OpenAI 称 GPT-Rosalind 智能体提出神经退行性疾病药物新线索
OpenAI 的 Greg Brockman 转发介绍，GPT-Rosalind 在药物发现上给出新线索：与 Perry 综合征相关的基因 DCTN1 在小鼠脑数据中被破坏后，胆固醇合成相关基因表达上升，GPT-Rosalind 据此提出胆固醇可能未到达神经元所需位置的机制解释。OpenAI 称与 PerturbAI 和 Scripps Research 合作，数千个 GPT-Rosalind 智能体并行工作，在 32 分钟内把数百万个小鼠脑细胞的基因表达结果与科学文献关联起来，该机制尚待科学家验证，合作正在扩展以寻找新药物靶点。
GPT-Rosalind surfaced a new lead for drug discovery: could restoring cholesterol transport protect neurons from degeneration? DCTN1 is a gene linked to Perry syndrome, a rare neurodegenerative disorder. In mouse-brain data, disrupting it increased expression of genes involved in making cholesterol. GPT-Rosalind suggested a possible explanation: cholesterol may not be reaching where neurons need it. That gives scientists a specific mechanism to test and, if confirmed, a direction for developing new treatments for neurodegenerative disorders. With @perturbai_tx and @scrippsresearch, a team of thousands of GPT-Rosalind agents worked in parallel, connecting gene-expression results from millions of mouse brain cells with scientific literature in just 32 minutes. We’re now expanding this collaboration to identify new drug targets. https://openai.com/index/scaling-ai-research-for-complex-biological-data/
